StreetInsider.com News Articles

Form SCHEDULE 13G Metagenomi Therapeutics, Filed by: Thomas Brian C.

Thu, 10 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260910/27048371.html

Form 4 Metagenomi Therapeutics, For: Sep 08 Filed by: Wein Matthew

Thu, 10 Sep 2026 15:47:00 -0400

si-local-file:///var/storage/secattach/20260910/27048191.html

Form 4 Metagenomi Therapeutics, For: Sep 08 Filed by: Irish Jian

Thu, 10 Sep 2026 15:40:00 -0400

si-local-file:///var/storage/secattach/20260910/27048174.html

Form 4 Metagenomi Therapeutics, For: Sep 08 Filed by: Wapnick Pamela

Thu, 10 Sep 2026 15:35:00 -0400

si-local-file:///var/storage/secattach/20260910/27048149.html

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Tue, 01 Sep 2026 08:00:00 -0400

EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference, being held in Boston, MA, on Thursday, September 10, 2026, at 12:45 p.m. ET.

The fireside chat presentation will be made available on the “News

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Tue, 01 Sep 2026 08:00:00 -0400

The fireside chat presentation will be made available on the “News

Metagenomi Inc (MGX) PT Lowered to $7 at Wells Fargo

Tue, 11 Aug 2026 06:56:35 -0400

Wells Fargo analyst Yanan Zhu lowered the price target on Metagenomi Inc (NASDAQ: MGX) to $7.00 (from $9.00) while maintaining a Overweight rating.

The analyst comments "MGX-001 remains on track for an IND submission in 4Q26, with IND-enabling studies, including GLP toxicology, expected to be completed this quarter. 2Q26 earnings results. Net loss per share was ($0.73) vs. consensus of ($0.55). The miss was primarily driven by a $2.6MM non-cash Ionis collaboration adjustment and higher- than-expected R&D expense. MGX ended the quarter with a cash position of $121MM, which is expected to fund operations through 4Q27 (consistent with prior guidance). Our

Metagenomi Inc (MGX) PT Lowered to $7 at Wells Fargo

Tue, 11 Aug 2026 06:56:35 -0400

Wells Fargo analyst Yanan Zhu lowered the price target on Metagenomi Inc (NASDAQ: MGX) to $7.00 (from $9.00) while maintaining a Overweight rating.

Metagenomi, Inc. (MGX) Tops Q2 EPS by 5c

Mon, 10 Aug 2026 18:23:12 -0400

Metagenomi, Inc. (NASDAQ: MGX) reported Q2 EPS of ($0.73), $0.05 better than the analyst estimate of ($0.78).

For earnings history and earnings-related data on Metagenomi, Inc. (MGX) click here.

Form 10-Q Metagenomi Therapeutics, For: Jun 30

Mon, 10 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260810/26898035.html

Form 10-Q Metagenomi Therapeutics, For: Jun 30

Mon, 10 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260810/26898035.html

Form 8-K Metagenomi Therapeutics, For: Aug 10

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897970.html

Form 8-K Metagenomi Therapeutics, For: Aug 10

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897970.html

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:05:00 -0400

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A

$120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027

EMERYVILLE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the second quarter ended June

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:05:00 -0400

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A

$120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027

Prolynx names CFO and CSO to advance obesity drug portfolio